KBC Group NV Purchases 1,328 Shares of Oscar Health, Inc. (NYSE:OSCR)

KBC Group NV grew its position in Oscar Health, Inc. (NYSE:OSCR) by 41.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,552 shares of the company’s stock after acquiring an additional 1,328 shares during the quarter. KBC Group NV’s holdings in Oscar Health were worth $97,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new position in Oscar Health in the second quarter worth $78,000. Quest Partners LLC bought a new position in shares of Oscar Health during the 2nd quarter worth about $93,000. Optimum Investment Advisors bought a new position in shares of Oscar Health during the 3rd quarter worth about $142,000. Amalgamated Bank boosted its position in shares of Oscar Health by 27.7% during the 2nd quarter. Amalgamated Bank now owns 6,727 shares of the company’s stock valued at $106,000 after acquiring an additional 1,458 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in Oscar Health in the third quarter valued at about $205,000. 75.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Oscar Health news, Vice Chairman Joshua Kushner bought 276,040 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $13.58 per share, for a total transaction of $3,748,623.20. Following the transaction, the insider now owns 5,031,262 shares in the company, valued at approximately $68,324,537.96. This trade represents a 5.80 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Victoria Baltrus sold 4,226 shares of Oscar Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $17.99, for a total transaction of $76,025.74. Following the sale, the chief accounting officer now owns 140,648 shares of the company’s stock, valued at approximately $2,530,257.52. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 1,055,478 shares of company stock worth $14,432,852 and sold 194,569 shares worth $3,433,319. 25.11% of the stock is currently owned by corporate insiders.

Oscar Health Price Performance

Oscar Health stock opened at $15.98 on Friday. Oscar Health, Inc. has a 52 week low of $7.29 and a 52 week high of $23.79. The firm has a market cap of $3.95 billion, a P/E ratio of -266.21 and a beta of 1.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73. The business’s fifty day moving average is $17.90 and its two-hundred day moving average is $18.21.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.33 billion. During the same period in the prior year, the company earned ($0.29) EPS. The firm’s revenue was up 68.3% compared to the same quarter last year. Equities research analysts forecast that Oscar Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Bank of America downgraded Oscar Health from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $21.00 to $13.50 in a report on Wednesday, November 6th. UBS Group assumed coverage on Oscar Health in a research note on Monday, October 7th. They issued a “neutral” rating and a $23.00 price target on the stock. Finally, Piper Sandler reiterated an “overweight” rating and set a $28.00 price objective on shares of Oscar Health in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.93.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.